Author:
Fernandez C. A.,Stewart E.,Panetta J. C.,Wilkinson M. R.,Morrison A. R.,Finkelman F. D.,Sandlund J. T.,Pui C. H.,Jeha S.,Relling M. V.,Campbell P. K.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference20 articles.
1. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ (1993) Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 11:1780–1786
2. Raetz EA, Salzer WL (2010) Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 32(7):554–563. doi: 10.1097/MPH.0b013e3181e6f003
3. Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG (1981) L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 41:4554–4558
4. Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R (2007) FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 12(8):991–998. doi: 10.1634/theoncologist.12-8-991
5. Muller HJ, Boos J (1998) Use of L-asparaginase in childhood ALL. Crit Rev Oncol/Hematol 28(2):97–113
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献